Anti-Human IgE/IGHE Reference Antibody (Ligelizumab, RUO) (HV064026)

Name: Anti-Human IgE/IGHE Reference Antibody (Ligelizumab, RUO)
Brand: abinScience
SKU: HV064026
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HV064026
Descripción	Ligelizumab (HV064026) is a research-grade recombinant antibody targeting Ig epsilon chain C region. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG1-kappa
Objetivo	IGHE, Ig epsilon chain C region, Ig epsilon chain C region ND, Immunoglobulin heavy constant epsilon
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P01854
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	CL-2C, 1322627-61-1
Fondo	Immunoglobulin heavy constant epsilon (IgE/IGHE) is a ~59 kDa protein. Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. 1. Schroeder, HW. et al. (2010) The Journal of allergy and clinical immunology 125, S41-52. PMID: 20176268 2. McHeyzer-Williams, M. et al. (2011) Nature reviews. Immunology 12, 24-34. PMID: 22158414 3. Teng, G. et al. (2007) Annual review of genetics 41, 107-20. PMID: 17576170
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)